GRI Bio
LA JOLLA, CA · Biotechnology · 9 employees
GRI Bio is a clinical stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells tha
Funding history
- Seed — $762K — Oct 2024
- Venture - Series Unknown — $15.6M — Apr 2023
- Seed — $1.3M — Dec 2022
Recent signals
- Oct 25, 2024: Raised $762K in Seed
- Apr 27, 2023: Raised $15.6M in Venture - Series Unknown
- Dec 22, 2022: Raised $1.3M in Seed
See plans & pricing → Track GRI Bio’s funding, hiring, and signals — with verified contacts — on Fundz.